Abstract
Far-UVC (222 nm UV-C light) is a promising tool to mitigate aerosol transmission of pathogens indoors. However, recent studies have raised concerns related to ozone (O3) production and secondary chemistry. In this study, we measured indoor O3 and ultra-fine particle (UFP, 17.5-289 nm) concentrations with and without 222 nm far-UVC (average fluence rate 1.7-1.8 µW/cm2) in a hotel quarantine facility in Baltimore (MD, USA). We obtained nearby outdoor O3 concentrations from the Environmental Protection Agency (EPA) website. In a sealed empty guest room, the average O3 concentrations were 3 ppb (UV off, 0.1-0.5 ACH), 16 ppb (UV on, 0.1 ACH) and 9 ppb (UV on, 0.5 ACH). In a standard guest room, the average O3 concentrations were 12 ppb (UV off, 1.4 ACH) and 14 ppb (UV on, 1.4 ACH), and correlated with outdoor concentrations (ρ = 0.65 – 0.74, p = 2*10−12 – 2*10−29). A linear regression model, adjusted for outdoor O3, estimated that use of far-UVC lamps increased the O3 concentration by 5.7 ppb (95% confidence interval (CI) 4.9 – 6.5 ppb) in the standard hotel room. Indoor O3 concentrations increased with far-UVC usage, however, the concentrations remained 6-12 ppb lower, on average, than outdoors and well below EPA ambient limits. We did not find a clear relationship between indoor UFP concentrations and UV usage. Although our study was limited by absence of direct outdoor measurements of local O3 and UFPs, our findings do not support a major impact of far-UVC on UFP concentrations in the real-world environment that we studied.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Balvi Filantropic Fund. The study got support also from NOAA/ARL, NIST, and MDE.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
